361 related articles for article (PubMed ID: 25681310)
1. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
Ludwig N; Kim YJ; Mueller SC; Backes C; Werner TV; Galata V; Sartorius E; Bohle RM; Keller A; Meese E
Neuro Oncol; 2015 Sep; 17(9):1250-60. PubMed ID: 25681310
[TBL] [Abstract][Full Text] [Related]
2. MiR-34a-3p alters proliferation and apoptosis of meningioma cells
Werner TV; Hart M; Nickels R; Kim YJ; Menger MD; Bohle RM; Keller A; Ludwig N; Meese E
Aging (Albany NY); 2017 Mar; 9(3):932-954. PubMed ID: 28340489
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.
Wallesch M; Pachow D; Blücher C; Firsching R; Warnke JP; Braunsdorf WEK; Kirches E; Mawrin C
J Neurol Sci; 2017 Sep; 380():112-121. PubMed ID: 28870549
[TBL] [Abstract][Full Text] [Related]
4. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
[TBL] [Abstract][Full Text] [Related]
5. The biological and diagnostic roles of MicroRNAs in meningiomas.
Wang L; Chen S; Liu Y; Zhang H; Ren N; Ma R; He Z
Rev Neurosci; 2020 Oct; 31(7):771-778. PubMed ID: 32697762
[TBL] [Abstract][Full Text] [Related]
6. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
7. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas.
Tsai WC; Hueng DY; Lin CR; Yang TC; Gao HW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187376
[TBL] [Abstract][Full Text] [Related]
9. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-195 Functions as a Tumor Suppressor by Directly Targeting Fatty Acid Synthase in Malignant Meningioma.
Song LR; Li D; Weng JC; Li CB; Wang L; Wu Z; Zhang JT
World Neurosurg; 2020 Apr; 136():e355-e364. PubMed ID: 31927122
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA Dysregulation in Canine Meningioma: RT-qPCR Analysis of Formalin-Fixed Paraffin-Embedded Samples.
Foiani G; Guelfi G; Mandara MT
J Neuropathol Exp Neurol; 2021 Sep; 80(8):769-775. PubMed ID: 34272938
[TBL] [Abstract][Full Text] [Related]
13. A microRNA expression signature predicts meningioma recurrence.
Zhi F; Zhou G; Wang S; Shi Y; Peng Y; Shao N; Guan W; Qu H; Zhang Y; Wang Q; Yang C; Wang R; Wu S; Xia X; Yang Y
Int J Cancer; 2013 Jan; 132(1):128-36. PubMed ID: 22674195
[TBL] [Abstract][Full Text] [Related]
14. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
[TBL] [Abstract][Full Text] [Related]
16. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
[TBL] [Abstract][Full Text] [Related]
17. Fatty Acid-binding Protein 4 Expression in Tumor Cells as a Potential Marker for Anaplastic Meningiomas.
Lee V; Smith TW; Arikan MÇ; Zhang L; Çataltepe O; Çataltepe S
Appl Immunohistochem Mol Morphol; 2021 Feb; 29(2):e10-e16. PubMed ID: 32324631
[TBL] [Abstract][Full Text] [Related]
18. Expression of miRNA-451 and miRNA-885 in Meningiomas.
Baran O; Karaoglu AC; Kara E; Budun O; Katar S; Yilmaz SG; Akdeniz FT; Ambarcioglu MA; Demirel N; Turk O; Ozdemir NG; Yaltirik CK; Isbir T
In Vivo; 2023; 37(6):2473-2479. PubMed ID: 37905647
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E1 expression and malignancy in meningiomas.
Pereira BJA; Santana Júnior PA; de Almeida AN; Cavalcante SG; de Melo KCM; de Aguiar PHP; Paiva WDS; Oba-Shinjo SM; Marie SKN
Clin Neurol Neurosurg; 2020 Mar; 190():105647. PubMed ID: 31945623
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.
Bosnyák E; Kamson DO; Guastella AR; Varadarajan K; Robinette NL; Kupsky WJ; Muzik O; Michelhaugh SK; Mittal S; Juhász C
Neuro Oncol; 2015 Sep; 17(9):1284-92. PubMed ID: 26092774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
